Randomized Phase III Trial Exploring the Use of LongActing Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorHOFF, Paulo M.
dc.contributor.authorSARAGIOTTO, Daniel F.
dc.contributor.authorBARRIOS, Carlos H.
dc.contributor.authorGIGLIO, Auro del
dc.contributor.authorCOUTINHO, Anelisa K.
dc.contributor.authorANDRADE, Aline C.
dc.contributor.authorDUTRA, Carolina
dc.contributor.authorFORONES, Nora M.
dc.contributor.authorCORREA, Mariangela
dc.contributor.authorPORTELLA, Maria do Socorro O.
dc.contributor.authorPASSOS, Vanessa Q.
dc.contributor.authorCHINEN, Renata N.
dc.contributor.authorEYLL, Brigitte van
dc.date.accessioned2016-09-09T19:17:48Z
dc.date.available2016-09-09T19:17:48Z
dc.date.issued2014
dc.description.abstractPurpose Chemotherapy-induced diarrhea (CID) is a relatively common adverse event in the treatment of patients with colorectal cancer. The LAR for Chemotherapy-Induced Diarrhea (LARCID) trial evaluated the efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this population. Patients and Methods Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm). Results A total of 139 patients were randomly assigned, most of whom received fluorouracil- and oxaliplatin-containing chemotherapy regimens. The rate of diarrhea was 76.1% in the experimental group (n = 68) and 78.9% in the control group (n = 71). Treatment with octreotide LAR did not prevent or reduce the severity of CID. Treatment choices for diarrhea management included loperamide in the majority of patients. No benefit from octreotide LAR was identified in terms of need for diarrhea treatment, opioids, or intravenous hydration or in the rate of hospitalization or quality of life. Conclusion This study could not prove the efficacy of octreotide LAR in the prevention of CID.
dc.description.indexMEDLINE
dc.identifier.citationJOURNAL OF CLINICAL ONCOLOGY, v.32, n.10, p.1006-1011, 2014
dc.identifier.doi10.1200/JCO.2013.50.8077
dc.identifier.eissn1527-7755
dc.identifier.issn1465-542X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/15986
dc.language.isoeng
dc.publisherBIOMED CENTRAL LTD
dc.relation.ispartofJournal of Clinical Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright BIOMED CENTRAL LTD
dc.subject.other2 different schedules
dc.subject.other1st-line treatment
dc.subject.otherrecommended guidelines
dc.subject.otheroral capecitabine
dc.subject.otheririnotecan
dc.subject.otherfluorouracil
dc.subject.othermulticenter
dc.subject.otherloperamide
dc.subject.othertherapy
dc.subject.otherleucovorin
dc.subject.wosOncology
dc.titleRandomized Phase III Trial Exploring the Use of LongActing Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalBARRIOS, Carlos H.:Hosp Sao Lucas, Porto Alegre, RS, Brazil
hcfmusp.author.externalGIGLIO, Auro del:Fac Med ABC, Ctr Estudos & Pesquisas Hematol & Oncol, Sao Paulo, Brazil
hcfmusp.author.externalCOUTINHO, Anelisa K.:Clin Assistencia Multidisciplinar Oncol, Salvador, BA, Brazil
hcfmusp.author.externalANDRADE, Aline C.:Biocancer, Belo Horizonte, MG, Brazil
hcfmusp.author.externalDUTRA, Carolina:Ctr Pesquisas Oncol, Florianopolis, SC, Brazil
hcfmusp.author.externalFORONES, Nora M.:Univ Fed Sao Paulo, Sao Paulo, Brazil
hcfmusp.author.externalCORREA, Mariangela:Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil
hcfmusp.author.externalPORTELLA, Maria do Socorro O.:Novartis Biociencias, Sao Paulo, Brazil
hcfmusp.author.externalPASSOS, Vanessa Q.:Novartis Pharmaceut, Florham Pk, NJ USA
hcfmusp.author.externalCHINEN, Renata N.:Novartis Biociencias, Sao Paulo, Brazil
hcfmusp.author.externalEYLL, Brigitte van:Inst Canc Arnaldo Vieira de Carvalho, Sao Paulo, Brazil
hcfmusp.citation.scopus37
hcfmusp.contributor.author-fmusphcPAULO MARCELO GEHM HOFF
hcfmusp.contributor.author-fmusphcDANIEL FERNANDES SARAGIOTTO
hcfmusp.description.beginpage1006
hcfmusp.description.endpage1011
hcfmusp.description.issue10
hcfmusp.description.volume32
hcfmusp.origemWOS
hcfmusp.origem.pubmed24516038
hcfmusp.origem.scopus2-s2.0-84901648923
hcfmusp.origem.wosWOS:000335138400009
hcfmusp.publisher.cityLONDON
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBajetta E, 2004, CANCER, V100, P279, DOI 10.1002/cncr.11910
hcfmusp.relation.referenceBarbounis V, 2001, SUPPORT CARE CANCER, V9, P258, DOI 10.1007/s005200000220
hcfmusp.relation.referenceBenson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132
hcfmusp.relation.referenceBorner MM, 2005, ANN ONCOL, V16, P282, DOI 10.1093/annonc/mdi047
hcfmusp.relation.referenceCartwright Thomas, 2005, Clin Colorectal Cancer, V5, P50, DOI 10.3816/CCC.2005.n.016
hcfmusp.relation.referenceCASCINU S, 1992, EUR J CANCER, V28A, P482
hcfmusp.relation.referenceCASCINU S, 1993, J CLIN ONCOL, V11, P148
hcfmusp.relation.referenceChen TL, 2000, J CLIN PHARMACOL, V40, P475, DOI 10.1177/00912700022009242
hcfmusp.relation.referenceClassen J, STRAHLENTHER ONKOL
hcfmusp.relation.referenceColucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
hcfmusp.relation.referenceFuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
hcfmusp.relation.referenceGEBBIA V, 1993, ANTI-CANCER DRUG, V4, P443, DOI 10.1097/00001813-199308000-00004
hcfmusp.relation.referenceGORDEN P, 1989, ANN INTERN MED, V110, P35
hcfmusp.relation.referenceGoumas P, 1998, ONCOLOGIST, V3, P50
hcfmusp.relation.referenceHoff PM, 2001, J CLIN ONCOL, V19, P2282
hcfmusp.relation.referenceIppoliti C, 1997, J CLIN ONCOL, V15, P3350
hcfmusp.relation.referenceIppoliti C, 1998, Oncol Nurs Forum, V25, P873
hcfmusp.relation.referenceKim TW, 2005, ACTA ONCOL, V44, P230, DOI 10.1080/02841860510029590
hcfmusp.relation.referenceMaroun J A, 2007, Curr Oncol, V14, P13, DOI 10.3747/co.2007.96
hcfmusp.relation.referenceMartenson JA, 2008, J CLIN ONCOL, V26, P5248, DOI 10.1200/JCO.2008.17.1546
hcfmusp.relation.referenceNational Comprehensive Network, 2011, MET COL CANC NCCN CL
hcfmusp.relation.referencePro B, 2001, INVEST NEW DRUG, V19, P341, DOI 10.1023/A:1010678214152
hcfmusp.relation.referenceRosenoff S, 2004, SUPPORT CARE CANCER, V12, P561, DOI 10.1007/s00520-003-0507-z
hcfmusp.relation.referenceRosenoff SH, 2004, EUR J CANCER CARE, V13, P380, DOI 10.1111/j.1365-2354.2004.00511.x
hcfmusp.relation.referenceRosenoff Stephen H, 2006, J Support Oncol, V4, P289
hcfmusp.relation.referenceRothenberg ML, 2001, J CLIN ONCOL, V19, P3801
hcfmusp.relation.referenceSaltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
hcfmusp.relation.referenceSastre J, 2005, J CLIN ONCOL, V23, P3545, DOI 10.1200/JCO.2005.03.004
hcfmusp.relation.referenceTournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
hcfmusp.relation.referenceTownsley CA, 2006, BRIT J CANCER, V94, P1136, DOI 10.1038/sj.bjc.6603055
hcfmusp.relation.referenceWadler S, 1998, J CLIN ONCOL, V16, P3169
hcfmusp.relation.referenceYavuz MN, 2002, INT J RADIAT ONCOL, V54, P195, DOI 10.1016/S0360-3016(02)02870-5
hcfmusp.relation.referenceZachariah B, 2010, JNCI-J NATL CANCER I, V102, P547, DOI 10.1093/jnci/djq063
hcfmusp.relation.referenceZidan J, 2001, ANN ONCOL, V12, P227, DOI 10.1023/A:1008372228462
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication706efa42-09fc-4065-8330-9391f2cbe840
relation.isAuthorOfPublicationaf368258-3287-4b35-a42b-c25867f205e6
relation.isAuthorOfPublication.latestForDiscovery706efa42-09fc-4065-8330-9391f2cbe840
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_HOFF_Randomized_Phase_III_Trial_Exploring_the_Use_of_2014.PDF
Tamanho:
146.72 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03